文献速递神经肿瘤

脑膜瘤CDKN2A/B状态与人口学、临床、手术及影像特征的关系探索

Exploring Demographic, Clinical, Surgical, and Imaging Features in Relation to CDKN2A/B Status in Meningiomas.
PubMed 文献 · World Neurosurg · 2025-12-02

本研究回顾性分析77例颅内脑膜瘤手术患者,其中44例(57.1%)接受CDKN2A/B检测,9例(11.6%)存在缺失。比较缺失阳性与阴性组,年龄、性别、术前肿瘤体积及影像学特征均无显著差异,部分缺失阳性肿瘤仍为WHO 1或2级,提示形态学与分子分级不一致,支持对所有脑膜瘤进行CDKN2A/B检测以准确进行WHO分类和风险评估。

要点

  • 人口学、临床及影像特征不能可靠预测CDKN2A/B缺失。
  • 部分CDKN2A/B缺失阳性脑膜瘤仍为WHO 1或2级。
  • 建议对所有脑膜瘤行CDKN2A/B检测以准确分级和风险评估。

核心结论

  • 在本队列中,人口学、临床或影像学特征不能可靠预测CDKN2A/B缺失。
  • 若干缺失阳性脑膜瘤被分类为WHO 1或2级,凸显形态学与分子分级间的脱节。
  • 这些发现支持对所有脑膜瘤进行CDKN2A/B检测以实现准确的WHO分类和风险评估。

研究设计与样本

  • 回顾性单中心研究,纳入2023年7月至2024年7月接受颅内脑膜瘤手术切除的患者。
  • 纳入标准包括组织学确诊脑膜瘤、术前MRI及通过FISH进行CDKN2A/B检测。
  • 共77例患者,其中44例(57.1%)接受了CDKN2A/B检测。

主要发现

  • 44例接受检测的患者中,9例(11.6%)显示CDKN2A/B缺失。
  • 中位年龄68岁(范围25-83),65%为女性。
  • 缺失阳性与阴性组在年龄(69 vs. 68,P = 0.36)、性别(女性66.7% vs. 65.9%,P = 0.89)或术前肿瘤体积(21.8 vs. 18.6 mL,P = 0.81)方面均无显著差异。
  • 影像学特征和组织学分级相似;Ki-67指数中位数为8%。
  • 无论CDKN2A/B状态如何,患者均被分类为WHO 1或2级。

关键数值与推荐

  • 2021年WHO分类认为CDKN2A/B纯合缺失足以定为3级,突显其预后意义。
  • 本研究中CDKN2A/B缺失率为11.6%(9/44例接受检测者)。

临床怎么用

  • 临床中不应依赖人口学、临床或影像特征来预测CDKN2A/B缺失。
  • 建议对所有脑膜瘤进行CDKN2A/B检测,以准确进行WHO分类和风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Meningiomas are the most common primary intracranial tumors, mostly benign, but some exhibit aggressive behavior. The 2021 WHO classification considers CDKN2A/B homozygous deletion as sufficient for grade 3 designation, highlighting its prognostic significance. It remains unclear whether demographic, clinical, or radiological features can predict deletion status or guide testing. METHODS: This retrospective single-center study reviewed patients who underwent surgical resection of intracranial meningiomas from July 2023 to July 2024. Inclusion criteria included histologically confirmed meningiomas, preoperative MRI, and CDKN2A/B testing via FISH. Imaging features assessed were tumor volume, edema, enhancement pattern, diffusion restriction, and CSF cleft preservation. Comparisons between CDKN2A/B-deleted and non-deleted groups were performed using Mann-Whitney U and Fisher's exact or Chi-square tests. RESULTS: Of 77 patients, 44 (57.1%) underwent CDKN2A/B testing, with 9 (11.6%) showing deletion. Median age was 68 years (range 25-83), and 65% were female. No significant differences between deletion-positive and -negative meningiomas were observed in age (69 vs. 68, P = 0.36), sex (66.7% vs. 65.9% female, P = 0.89), or preoperative tumor volume (21.8 vs. 18.6 mL, P = 0.81). Imaging features and histological grades were similar; Ki-67 index median was 8%. Patients were classified as WHO grade I or II regardless of CDKN2A/B status. CONCLUSIONS: In this cohort, demographic, clinical, or radiological features did not reliably predict CDKN2A/B deletion. Several deletion-positive meningiomas were classified as grade 1 or 2, underscoring the disconnect between morphology and molecular grading. These findings support universal CDKN2A/B testing for accurate WHO classification and risk assessment.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Abofani H, Ben-Moyal O, Cohen ZR, et al. Exploring Demographic, Clinical, Surgical, and Imaging Features in Relation to CDKN2A/B Status in Meningiomas. World Neurosurg. 2025. PMID: 41344397. doi:10.1016/j.wneu.2025.124699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。